Prix Precision BioSciences Inc (DTIL)

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 67 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.